Collectively, these data highlight the potential of CXCR4 and CCR7 chemokine receptors as powerful therapeutic targets for the treatment of T-ALL patients with NOTCH1 activating mutations, especially for those with CNS involvement (Figure 3). This evidence concerns the gene CXCR4 and acute lymphoblastic leukemia.